Articles On Race Oncology (ASX:RAC)

The S&P/ASX 200 Index (ASX: XJO) endured a rather savage pullback this Wednesday, as investors pulled back after the strong start to the week that we saw over the past two trading days. As of today's...

RAC welcomes Investigational New Drug approval for cancer treatment in Korea Company plans to start patient recruitment shortly at four sites for the Phase 1 clinical trial Korean MFDS IND approval rigour is similar to that provided by the...

Good Afternoon and welcome to HotCopper’s Market Close for Wednesday 24th of September, I’m Jon Davidson. It was a bad start to the day as far as getting back towards 9,000pts goes, and then it got worse. We learned today that Australian he...

Race Oncology (ASX:RAC) has received approval for an investigational new drug (IND) from Korea’s health and drug regulator MFDS, with a phase one clinical trial for Race’s RC220 drug of interest now to go ahead in the Republic. Listen to...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 1% to 8,758.7 points. Four ASX shares that are not letting that hold them back are...

Current cancer imaging tools are “not good enough”, Imagion chief Bob Proulx says Micro-x announces second grant in the space of two days Race Oncology wins Korean trial assent … in South Korea, of course   Imagion Biosystems (ASX:IBX) sa...

Biotechnology stocks can be high-risk but also high-reward. The key is latching on to one with a promising product pipeline and the ability to bring it to market. Wilsons Advisory's healthcare analysts believe Immutep Ltd (ASX: IMM) may...

The All Ordinaries Index (ASX: XAO) is down in morning trade today, but that's not holding back this rocketing ASX All Ords gold stock. The surging miner in question is Barton Gold Holdings Ltd (ASX: BGD). Barton Gold only officially joined...

The market may be tumbling today, but that hasn't stopped one ASX All Ords share from racing higher. Its shares are up a sizeable 9% to $3.26 at the time of writing. Which ASX All Ords share? The share in question today is Race Oncology Ltd...

ASX pares back early gains to lift 0.32pc Healthcare, tech, utilities drive gains Resources sector drags as gold prices slip from highs ASX gets clean bill of health The ASX was looking a little healthier today, adding 0.32% or 28.3 poi...

Good afternoon, and welcome to the HotCopper HotList Top 10. Every week, hundreds of companies go through the ups and downs of the ASX trading rollercoaster, with fortunes made and equity lost each time the Aussie bourse opens – which is wh...

Tylah Tully chats with Race Oncology (ASX:RAC) CEO Dr Daniel Tillett about the company’s major breakthrough submitting a new composition of matter patent application for the Ee-bisantrene compound.  Race has identified the long-studied canc...

ASX closes in the green on positive trading day for energy and resources Big-gun miners help bring bourse back out of the tunnel Goldies rally, too – and we may as well keep this bullet point as standard for the moment   The ASX closed 0....

Race Oncology scientists find a new way of patenting the active chemical form of bisantrene New composition of matter patent application submitted which, if granted, will provide IP protection for 20 years Race says the discovery fundament...

With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets – which is why getting out in front of those trends is so important for any trader worth their salt. Listen to the H...

Highlights Gold stocks continued to show strength alongside energy counters Major developments shaped trading in leading mining and retail companies Corporate actions created headlines across large and small-cap segments...

The All Ordinaries Index (ASX: XAO) is up 0.3% in morning trade today, with plenty of help from this surging ASX All Ords healthcare share. The rocketing stock in question is clinical stage biopharmaceutical company Race Oncology Ltd (ASX:...

Good Afternoon and welcome to Market Close for Monday 15 September, I’m Jon Davidson. September sell-off season continues, and that was evident today across gold miners as investors take the downturn to scrape profits. After gold prices hav...

Highlights Energy names face operational and cost headwinds Healthcare heavyweights and med-tech reprice expectations Materials narrative pivots as gold output guidance tightens Midday trade turns cautious: energy face...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

Ignite Partners is bringing the buzz to Hong Kong with a two-day power event packed with dynamic one-on-ones between top CEOs and hand-picked investors. The Grand Ballroom, 1 Harbour Road, Wan Chai, Hong Kong 15 – 16 October 2025 Pre-ar...

Highlights US policy changes back research on rare diseases Australian biotech firms gain momentum New regulatory clarity benefits orphan drug development Australian biotech companies focused on rare disease therapies are gaining...

MoneyTalks is Stockhead’s drill down into what stocks investors are looking at right now. We tap our list of experts to hear what’s hot, their top picks and what they’re looking out for. Today we hear from Australia’s Summit Biotech Fund ma...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights Breaks down biotech company stages from discovery to commercialisation Explores real-world examples of ASX-listed biotech companies Offers insight into navigating risk across drug development phases Biotech investing is...

Race Oncology (ASX:RAC) has captured the most attention on the HotCopper forums today after successfully – and safely – dosing its first patient with RC220 and RC220 in combination with doxorubicin. Listen to the HotCopper podcast for in...

Trigg Minerals (ASX:TMG) has drawn the most attention on the HotCopper forums through Thursday trade after the mining company mysteriously halted just before open. Holders were left “a bit worried” across the boards. Listen to the HotCop...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

In this HotCopper Capital Compass interview, Race Oncology (ASX:RAC) chairman Dr Pete Smith discusses the company’s “safe and successful” Phase One clinical trials and the RC220 plus doxorubicin dosing done at the time. Listen to the Hot...

Amplia Therapeutics (ASX:ATX) has been the most watched on HotCopper forums through today after huge results from its ACCENT trials set up to look into how its FAK inhibitor, Narmafotinib, combats cancer. Listen to the HotCopper podcast...

Highlights ASX 200 futures hint at a soft open amid global macro caution Fed maintains interest rates; inflation outlook revised upward Small-cap actions drive interest with regulatory approvals, trial updates The Australian share...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Tylah Tully speaks with Race Oncology (ASX:RAC) CEO Daniel Tillett after the company dosed the first patient in its RC220 Phase 1 solid tumour trial. Race has reformulated RC220, after the initial formulation caused crystallisation in the b...

Global pharmaceutical leader Herwig Janssen appointed Tryptamine non-executive chairman Janssen held senior leadership roles with multinational pharmaceutical company Johnson & Johnson Chris Ntoumenopoulos will transition to role of ex...

Tryptamine is focused on using psilocybin to treat difficult mental health and neurological conditions In league with Swinburne University, the company will launch a groundbreaking binge eating disorder trial using intravenous delivery Wit...

Highlights: ASX 200 futures edged higher in early trade, tracking gains from global equities and a strong US jobs report Positive sector moves led by information technology, real estate, and health care, while materials saw subdu...

Highlights Race Oncology appoints Dr Jose Iglesias as Chief Medical Officer and Dr Simon Fisher as Vice President of Clinical. RC220 development progresses with a focus on solid tumours and acute myeloid leukaemia. The leade...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

First patient dosed at lead trial site, Southside Cancer Care. Phase 1 trial to determine safety, tolerability and pharmacokinetic data, plus maximum tolerated combined dose of RC220 with chemotherapeutic doxorubicin. Up to 33 patients to...

The ASX200 closed up 0.24% at 8,145 points. The IT sector surged and was the best performer, up 4%, followed by Real Estate, up 1.6%, and Staples, up 1.4%. Energy shed some of yesterday’s gains and finished down, 1.35%, followed by Ma...

Highlights Race Oncology commences Phase 1 solid tumour trial with initial patient dosed safely at Miranda, NSW RC220 explored in combination with doxorubicin, leveraging prior bisantrene research and preclinical outcomes Tr...

Highlights ASX 200 advances as tech sector rallies and large-cap miners ease Andromeda achieves breakthrough in ultra-high purity alumina production Tesla leadership speculation rises amid US economic shifts and trade talks...

Telix’s quarterly sales reflect first revenue from the company’s recent purchase of a US nuclear medicine manufacturer Island Pharma hopes to lift the kimono on its dengue fever trial next month Race Oncology kicks off its cancer-busting,...

Highlights: Errawarra Resources advances its exploration at the Elizabeth Hill Silver Project Race Oncology expands its clinical trials with a new research site RareX pursues licensing for the Mrima Hill project in collabora...

The ASX200 has been flat, down 0.1% at 7,812 points in early afternoon trades. Errawarra Resources (ASX:ERW) has been among the most watched on HotCopper forums today after sharing details on the rapid advancement of its exploration prog...

Highlights  Wall Street downturn triggers expected dip in ASX open Global uncertainties, rate cut pressure shake investor sentiment Race Oncology advances cancer trial with new site activation  The Australian share market is expec...

Race Oncology activates first Australian site for Phase I trial of potential cancer and cardioprotective therapeutic RC220, enabling patient enrolments This comes after governance approval announced today, and Human Research Ethics Committ...

Donald Trump exempts “pharmaceuticals” from his tariff blitz ASX device makers mull their US manufacturing plans as Ansell shares plunge Race and Imugene progress their early-stage oncology trials   Liberation Day has spared the pharmaceu...

Highlights St George Mining Ltd announces a maiden Mineral Resource Estimate for the Araxá Project in Brazil, highlighting high-grade niobium and rare earths. ASX 200 futures show a modest gain as investors await updates from the...